Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Czerwiec, Frank S."" wg kryterium: Autor


Tytuł :
Performance of an Artificial Multi-observer Deep Neural Network for Fully Automated Segmentation of Polycystic Kidneys
Autorzy :
Kline, Timothy L.
Korfiatis, Panagiotis
Edwards, Marie E.
Blais, Jaime D.
Czerwiec, Frank S.
Harris, Peter C.
King, Bernard F.
Torres, Vicente E.
Erickson, Bradley J.
Pokaż więcej
Źródło :
Journal of Digital Imaging: The Journal of the Society for Computer Applications in Radiology. August 2017 30(4):442-448
Czasopismo naukowe
Tytuł :
Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease
Autorzy :
Gansevoort, Ron T
van Gastel, Maatje DA
Chapman, Arlene B
Blais, Jaime D
Czerwiec, Frank S
Higashihara, Eiji
Lee, Jennifer
Ouyang, John
Perrone, Ronald D
Stade, Katrin
Torres, Vicente E
Devuyst, Olivier
Pokaż więcej
Temat :
Institute of Physiology
570 Life sciences
biology
610 Medicine & health
Nephrology
Źródło :
Gansevoort, Ron T; van Gastel, Maatje DA; Chapman, Arlene B; Blais, Jaime D; Czerwiec, Frank S; Higashihara, Eiji; Lee, Jennifer; Ouyang, John; Perrone, Ronald D; Stade, Katrin; Torres, Vicente E; Devuyst, Olivier (2019). Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease. Kidney International, 96(1):159-169.
Opis pliku :
application/pdf
Tytuł :
Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial
Autorzy :
Torres, Vicente E.
Chapman, Arlene B.
Devuyst, Olivier
Gansevoort, Ron T.
Perrone, Ronald D.
Dandurand, Ann
Ouyang, John
Czerwiec, Frank S.
Blais, Jaime D.
Pokaż więcej
Temat :
chronic kidney disease
polycystin kidney disease
CYST GROWTH
Institute of Physiology
610 Medicine & health
vasopressin
PROGRESSION
autosomal dominant polycystic kidney disease
Nephrology, Transplantation
VOLUME
humanities
OUTCOMES
Clinical Research
behavioral disciplines and activities
CLINICAL-TRIALS
vasopressin v2 receptor antagonist
ORIGINAL ARTICLES
570 Life sciences
biology
Źródło :
Nephrology, Dialysis, Transplantation, 33(3), 477 - 489. Oxford University Press
Nephrology Dialysis Transplantation
Torres, Vicente E; Chapman, Arlene B; Devuyst, Olivier; Gansevoort, Ron T; Perrone, Ronald D; Dandurand, Ann; Ouyang, John; Czerwiec, Frank S; Blais, Jaime D (2018). Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial. Nephrology, Dialysis, Transplantation, 33(3):477-489.
Opis pliku :
application/pdf
Tytuł :
Development of the Autosomal Dominant Polycystic Kidney Disease Impact Scale: A New Health-Related Quality-of-Life Instrument
Autorzy :
Oberdhan, Dorothee
Cole, Jason C
Krasa, Holly B
Cheng, Rebecca
Czerwiec, Frank S
Hays, Ron D
Chapman, Arlene B
Perrone, Ronald D
Pokaż więcej
Temat :
ADPKD
patient-centered outcomes
Polycystic kidney
PRO instrument
Public Health and Health Services
Fatigue
Focus Groups
Urology & Nephrology
patient-reported outcome
autosomal dominant
Female
pain
urologic and male genital diseases
Middle Aged
disease burden
Emotional Adjustment
Reproducibility of Results
Physical Functional Performance
kidney diseases
Patient Reported Outcome Measures
Clinical Sciences
Cost of Illness
quality of life
Surveys and Questionnaires
Humans
Male
cystic
female genital diseases and pregnancy complications
Źródło :
Oberdhan, D; Cole, JC; Krasa, HB; Cheng, R; Czerwiec, FS; Hays, RD; et al.(2018). Development of the Autosomal Dominant Polycystic Kidney Disease Impact Scale: A New Health-Related Quality-of-Life Instrument. AMERICAN JOURNAL OF KIDNEY DISEASES, 71(2), 225 - 235. doi: 10.1053/j.ajkd.2017.08.020. UCLA: Retrieved from: http://www.escholarship.org/uc/item/71g855jk
American Journal of Kidney Diseases, vol 71, iss 2
Opis pliku :
application/pdf
Tytuł :
Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial.
Autorzy :
Torres, Vicente E
Chapman, Arlene B
Devuyst, Olivier
Gansevoort, Ron T
Perrone, Ronald D
Dandurand, Ann
Ouyang, John
Czerwiec, Frank S
Blais, Jaime D
TEMPO 4:4 Trial Investigators
Pokaż więcej
Temat :
Chronic kidney disease
Polycystin kidney disease
humanities
behavioral disciplines and activities
Vasopressin
Vasopressin v2 receptor antagonist
Autosomal dominant polycystic kidney disease
Źródło :
Nephrology, Dialysis, Transplantation, Vol. 33, no. 3, p. 477-489 (2018)
Tytuł :
Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease
Autorzy :
Torres, Vicente E
Chapman, Arlene B
Devuyst, Olivier
Gansevoort, Ron T
Perrone, Ronald D
Koch, Gary
Ouyang, John
McQuade, Robert D
Blais, Jaime D
Czerwiec, Frank S
Sergeyeva, Olga
Pokaż więcej
Temat :
VOLUME
ADPKD
CYST GROWTH
SECRETION
GLOMERULAR-FILTRATION-RATE
CLINICAL-TRIALS
urologic and male genital diseases
VASOPRESSIN
PROGRESSION
MODEL
RENAL-DISEASE
Źródło :
New England Journal of Medicine, 377(20), 1930 - 1942. MASSACHUSETTS MEDICAL SOC
Opis pliku :
application/pdf
Tytuł :
Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease
Autorzy :
Torres, Vicente E
Chapman, Arlene B
Devuyst, Olivier
Gansevoort, Ron T
Perrone, Ronald D
Koch, Gary
Ouyang, John
McQuade, Robert D
Blais, Jaime D
Czerwiec, Frank S
Sergeyeva, Olga
Pokaż więcej
Temat :
Institute of Physiology
570 Life sciences
biology
610 Medicine & health
Źródło :
Torres, Vicente E; Chapman, Arlene B; Devuyst, Olivier; Gansevoort, Ron T; Perrone, Ronald D; Koch, Gary; Ouyang, John; McQuade, Robert D; Blais, Jaime D; Czerwiec, Frank S; Sergeyeva, Olga (2017). Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease. New England Journal of Medicine, 377(20):1930-1942.
Opis pliku :
application/pdf
Tytuł :
Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial
Autorzy :
Cornec-Le Gall, Emilie
Blais, Jaime D
Irazabal, Maria V
Devuyst, Olivier
Gansevoort, Ron T
Perrone, Ron D
Chapman, Arlene B
Czerwiec, Frank S
Ouyang, John
Heyer, Christina M
Senum, Sarah R
Le Meur, Yannick
Torres, Vicente E
Harris, Peter C
Pokaż więcej
Temat :
ADPKD
TOLVAPTAN
MOLECULAR DIAGNOSTICS
Institute of Physiology
GENE
610 Medicine & health
[SDV.IMM]Life Sciences [q-bio]/Immunology
autosomal dominant polycystic kidney disease
Nephrology, Transplantation
VOLUME
MUTATIONS
IDENTIFICATION
genetics
Clinical Research
DESIGN
ORIGINAL ARTICLES
TEMPO 3/4
Journal Article
570 Life sciences
biology
PKD1
PKD2
Źródło :
Cornec-Le Gall, Emilie; Blais, Jaime D; Irazabal, Maria V; Devuyst, Olivier; Gansevoort, Ron T; Perrone, Ron D; Chapman, Arlene B; Czerwiec, Frank S; Ouyang, John; Heyer, Christina M; Senum, Sarah R; Le Meur, Yannick; Torres, Vicente E; Harris, Peter C (2018). Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial. Nephrology, Dialysis, Transplantation, 33(4):645-652.
Nephrology Dialysis Transplantation
Nephrology, Dialysis, Transplantation, 33(4), 645 - 652. Oxford University Press
Nephrology Dialysis Transplantation, Oxford University Press (OUP), 2017, ⟨10.1093/ndt/gfx188⟩
Opis pliku :
application/pdf
Tytuł :
Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease
Autorzy :
Grantham, Jared J
Chapman, Arlene B
Blais, Jaime
Czerwiec, Frank S
Devuyst, Olivier
Gansevoort, Ron T
Higashihara, Eiji
Krasa, Holly
Zhou, Wen
Ouyang, John
Perrone, Ronald D
Torres, Vicente E
Pokaż więcej
Temat :
Institute of Physiology
570 Life sciences
biology
610 Medicine & health
Źródło :
Grantham, Jared J; Chapman, Arlene B; Blais, Jaime; Czerwiec, Frank S; Devuyst, Olivier; Gansevoort, Ron T; Higashihara, Eiji; Krasa, Holly; Zhou, Wen; Ouyang, John; Perrone, Ronald D; Torres, Vicente E (2017). Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease. Nephrology, Dialysis, Transplantation, 32(6):969-975.
Tytuł :
Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease
Autorzy :
Grantham, Jared J.
Chapman, Arlene B.
Blais, Jaime
Czerwiec, Frank S.
Devuyst, Olivier
Gansevoort, Ron T.
Higashihara, Eiji
Krasa, Holly
Zhou, Wen
Ouyang, John
Perrone, Ronald D.
Torres, Vicente E.
Pokaż więcej
Temat :
CHEMOATTRACTANT PROTEIN-1
chemokine
renal biomarker
CYST GROWTH
OBSTRUCTION
PROGRESSION
disease progression
BRAIN
interstitial inflammation
RENAL-DISEASE
VOLUME
CELLS
Original Articles
URINARY BIOMARKERS
INJURY
Basic Research
chronic renal disease
Źródło :
Nephrology Dialysis Transplantation
Nephrology, Dialysis, Transplantation, 32(6), 969 - 975. Oxford University Press
Tytuł :
Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial
Autorzy :
Devuyst, Olivier
Chapman, Arlene B
Gansevoort, Ron T
Higashihara, Eiji
Perrone, Ronald D
Torres, Vicente E
Blais, Jaime D
Zhou, Wen
Ouyang, John
Czerwiec, Frank S
Pokaż więcej
Temat :
Institute of Physiology
570 Life sciences
biology
610 Medicine & health
Źródło :
Devuyst, Olivier; Chapman, Arlene B; Gansevoort, Ron T; Higashihara, Eiji; Perrone, Ronald D; Torres, Vicente E; Blais, Jaime D; Zhou, Wen; Ouyang, John; Czerwiec, Frank S (2017). Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial. Journal of the American Society of Nephrology (JASN), 28(5):1592-1602.
Opis pliku :
application/pdf

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies